News & Events about Maxcyte Inc.
MaxCytes Scientific Advisory Board will provide guidance to shape the technical direction of the companys innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicinesROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: ...
Curamys to use MaxCytes Flow Electroporation technology and ExPERT platform to help advance its cell fusion technology.ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling ...
MaxCyte, Inc. (NASDAQ:MXCT Get Rating) EVP Thomas M. Ross sold 4,282 shares of the businesss stock in a transaction that occurred on Tuesday, October 11th. The stock was sold at an average price of $6.51, for a total transaction of $27,875.82. The transaction was disclosed in a filing...
MaxCyte (NASDAQ:MXCT Get Rating) had its target price raised by BTIG Research from $10.00 to $11.00 in a report issued on Sunday, The Fly reports. MaxCyte Price Performance Shares of MXCT opened at $5.87 on Friday. The stock has a market capitalization of $596.55 million and a P/E ratio of -...
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, ...